What is Acumen Pharmaceuticals, Inc.'s market cap?

Acumen Pharmaceuticals, Inc. (ABOS) has a market capitalization of $195.0M and trades on NASDAQ.

Who are Acumen Pharmaceuticals, Inc.'s competitors?

Acumen Pharmaceuticals, Inc.'s key competitors include Biogen Inc., Eli Lilly and Company, Alzamend Neuro, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Acumen Pharmaceuticals, Inc. partner with?

Acumen Pharmaceuticals, Inc.'s notable partners include JCR Pharmaceuticals Co. Ltd., Halozyme, Inc., Biogen Inc., and others.

Where is Acumen Pharmaceuticals, Inc. headquartered?

Acumen Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 52 people. It has been publicly traded since 2021.

Acumen Pharmaceuticals, Inc.

ABOS

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing disease-modifying immunotherapies for Alzheimer’s disease.

Market cap

$195.01M+148%

Table of contents

Earnings

Q1 2026 report

May 12, 2026

EPS-$0.33Beat by $0.07

Read the full report

Next report

Aug 11, 2026 (in a month)

EPS estimate-$0.39

Competitors

By market cap

Eli Lilly$1.09T+56.4%

Biogen$29.4B+54.0%

Apogee Therapeutics, Inc.$10.0B+339%

Rezolute$494.0M+14.3%

Neumora Therapeutics, Inc.$305.7M+111%

MacroGenics$290.5M+239%

Acumen Pharmaceuticals, Inc.$195.0M+178%

Alzamend Neuro, Inc.$4.4M-47.1%

By revenue growth

Eli Lilly+47.4%

Biogen+1.2%

By net margin

Eli Lilly34.99%+12.3pp

Biogen14.3%-0.8pp

Profile

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing disease-modifying immunotherapies for Alzheimer’s disease. The company targets soluble amyloid-beta oligomers (AßOs), which are believed to be a primary toxin responsible for the initiation and progression of Alzheimer's pathology. Their lead candidate is designed to provide a more selective and safer treatment profile compared to traditional plaque-targeting therapies.

Competitive position

A pioneer in AßO-selective antibody research with a first-in-class target engagement assay for Alzheimer's disease.

GeographiesUnited States, Global

Customer segmentsPatients with Alzheimer's disease, Patients with mild cognitive impairment

Business modelR&D intensive, Biopharmaceutical licensing

SuppliersContract manufacturing organizations, Clinical research organizations, Specialized laboratory providers

CustomersPharmaceutical licensing partners, Specialty pharmacies, Hospitals and infusion centers

CountryUnited States of America

Listed2021

Employees52.0

CEODaniel J. O'Connell

SectorHealthcare

IndustryBiotechnology

Websiteacumenpharm.com

FilingsSEC EDGAR

Questions, answered.

What is Acumen Pharmaceuticals, Inc.'s market cap?: Acumen Pharmaceuticals, Inc. (ABOS) has a market capitalization of $195.0M and trades on NASDAQ.
Who are Acumen Pharmaceuticals, Inc.'s competitors?: Acumen Pharmaceuticals, Inc.'s key competitors include Biogen Inc., Eli Lilly and Company, Alzamend Neuro, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Acumen Pharmaceuticals, Inc. partner with?: Acumen Pharmaceuticals, Inc.'s notable partners include JCR Pharmaceuticals Co. Ltd., Halozyme, Inc., Biogen Inc., and others.
Where is Acumen Pharmaceuticals, Inc. headquartered?: Acumen Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 52 people. It has been publicly traded since 2021.